Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|3|310-319

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.3, 2015-05, pp. : 310-319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 320-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA

By  

International Journal of Technology Assessment in Health Care, Vol. 32, Iss. 5, 2016-12 ,pp. : 337-347

Cambridge University Press

Access to resources Recommend Favorite

Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis

By Odeyemi Isaac A. O.   Danø Anne M.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 239-250

Informa Healthcare

Access to resources Recommend Favorite

Prospective, observational study of plasma‐derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : e122-e124

John Wiley & Sons Inc

Access to resources Recommend Favorite